Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis response Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis additional cost-effectiveness analyses This page was last updated: 01 March 2013